Calidi Biotherapeutics(CLDI) - 2022 Q1 - Quarterly Report
Calidi Biotherapeutics(CLDI)2022-05-11 00:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to to Commission File Number: 001-40789 FIRST LIGHT ACQUISITION GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 86-2967193 (St ...